Augmentation of immune response against glioblastoma by intradermal administration of irradiated tumor cell hybrids: a Phase II clinical trial with safety lead-in. Save

Date Added
December 20th, 2016
PRO Number
Pro00058836
Researcher
Sebastiano Gattoni-celli

Silhouette
Keywords
Brain Tumor, Cancer/Brain, Glioblastoma
Summary

Patients diagnosed with glioblastoma multiforme, the most severe brain tumor,
will undergo standard treatment. This treatment is (a) surgery to remove as much of the tumor as possible and (b) radiation/chemotherapy. This study will collect some of the tumor when the surgical procedure is performed. The tumor tissue will then be processed and developed into a patient specific cancer vaccine. This will take about seven weeks. The patient will then receive their patient-specific vaccine for a total of 10 doses over a period of 16 weeks. Hopefully, the vaccine will prevent any resultant GBM tumor cells from recurring, thus extending survival rates.

Institution
MUSC
Recruitment Contact
Linda Ambrose
843-789-7816
linda.ambrose@va.gov

Change_preferences

-- OR --

Create_login